News Boehringer bags FDA okay for new pulmonary fibrosis drug Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?
News PhRMA unveils DTC sales site, as more drugmakers join in Pharma is embracing DTC selling of medicines in the US, and industry body PhRMA has stepped in to help cut out the middlemen in the supply chain.
R&D Six things we learned about the obesity market at LSX 2025 In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.
News Boehringer back in cancer with Hernexeos approval Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.
News Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.
News Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.